A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma

This Phase III study is testing whether adding an immunotherapy drug (cadonilimab) to standard chemotherapy (SOX regimen) before and after surgery improves outcomes for people with resectable stomach or gastroesophageal junction cancer. **You may be eligible if...** - You have been diagnosed with stomach cancer or cancer where the stomach meets the esophagus, confirmed by biopsy - Your cancer is considered surgically removable (resectable, stage T3–T4b) - You are in good health and able to carry out daily activities (ECOG 0–1) - Your life expectancy is at least 6 months - You have not received any prior cancer treatment for this diagnosis - Your organ function (blood, liver, kidneys) is adequate **You may NOT be eligible if...** - Your cancer has spread to distant organs (metastatic) - You have a different type of cancer (not adenocarcinoma) - You are taking immunosuppressive medications - You have an active autoimmune disease - You have an active or serious infection - You have another active cancer requiring treatment Talk to your doctor to see if this trial is right for you.